Tus kws kho mob
Dry Eye Disease - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2024
Cov Ntaub Ntawv thiab Cov Txiaj Ntsig Ua Tau Los Ntawm Cov Foos
Nthuav pom cov txiaj ntsig tshwm sim 1331 - 1340 ntawm 3165
Tus kws kho mob
Benign Prostatic Hypertrophy (BPH) - Medicaid
Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2024
Tus kws kho mob
Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors and Combinations - Medicaid
Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2024
Tus kws kho mob
Neurotrophic Keratitis - Medicaid
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2024
Tus kws kho mob
Neurotrophic Keratitis - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2024
Tus kws kho mob
Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blocker (Corlanor) - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2024
Tus kws kho mob
Proton Pump Inhibitors (PPI's) - Medicaid
Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2024
Tus kws kho mob
Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors and Combinations - Commercial
Step Therapy, Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 01, 2024
Tus kws kho mob
QP73-24 Prime Therapeutics/Magellan Rx Management (medical pharmacy solutions program) to become “Prime Therapeutics Management”
Hnub Tim pib siv tau lub khoos kas: Lub Cuaj Hlis Ntuj Tim 25, 2024
Tus kws kho mob
QP71-24 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective October 1, 2024
Hnub Tim pib siv tau lub khoos kas: Lub Cuaj Hlis Ntuj Tim 11, 2024